JP2014510590A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510590A5
JP2014510590A5 JP2014501668A JP2014501668A JP2014510590A5 JP 2014510590 A5 JP2014510590 A5 JP 2014510590A5 JP 2014501668 A JP2014501668 A JP 2014501668A JP 2014501668 A JP2014501668 A JP 2014501668A JP 2014510590 A5 JP2014510590 A5 JP 2014510590A5
Authority
JP
Japan
Prior art keywords
combination product
composition
product
composition according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014501668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510590A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/055979 external-priority patent/WO2012131095A1/en
Publication of JP2014510590A publication Critical patent/JP2014510590A/ja
Publication of JP2014510590A5 publication Critical patent/JP2014510590A5/ja
Pending legal-status Critical Current

Links

JP2014501668A 2011-03-31 2012-04-02 フィラー製品および少なくとも１つの生体吸収性および生分解性シリカベースの材料を含む組成物 Pending JP2014510590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470211P 2011-03-31 2011-03-31
US61/470,211 2011-03-31
PCT/EP2012/055979 WO2012131095A1 (en) 2011-03-31 2012-04-02 Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material

Publications (2)

Publication Number Publication Date
JP2014510590A JP2014510590A (ja) 2014-05-01
JP2014510590A5 true JP2014510590A5 (enExample) 2015-05-21

Family

ID=45953116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014501668A Pending JP2014510590A (ja) 2011-03-31 2012-04-02 フィラー製品および少なくとも１つの生体吸収性および生分解性シリカベースの材料を含む組成物

Country Status (6)

Country Link
US (1) US20140065221A1 (enExample)
EP (1) EP2691115A1 (enExample)
JP (1) JP2014510590A (enExample)
BR (1) BR112013025157A2 (enExample)
CA (1) CA2830654A1 (enExample)
WO (1) WO2012131095A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
CA2816576C (en) 2010-11-01 2020-06-02 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
KR101647182B1 (ko) * 2014-02-10 2016-08-23 박용호 피부조직 복원용 필러엑스(Filler X) 조성물
US11389563B2 (en) 2017-06-12 2022-07-19 Advanced Aesthetic Technologies, Inc. Dermal filler
CN112384258A (zh) 2018-05-09 2021-02-19 约翰·霍普金斯大学 用于细胞和组织递送的纳米纤维-水凝胶复合物
IL307979B2 (en) 2018-05-09 2025-08-01 Univ Johns Hopkins Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
KR102264957B1 (ko) * 2019-06-21 2021-06-17 고려대학교 산학협력단 체내 부피 유지 제제 및 이의 제조방법
US11896715B2 (en) 2019-06-21 2024-02-13 Korea University Research And Business Foundation In vivo bulking agent, injection comprising same, and preparation method therefor
JP2025041170A (ja) * 2023-09-13 2025-03-26 昌毅 本田 肛門狭窄化治療法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777041A (en) * 1986-08-07 1988-10-11 Charles Of The Ritz Group Ltd. Wrinkle treatment formulation
US5204382A (en) * 1992-02-28 1993-04-20 Collagen Corporation Injectable ceramic compositions and methods for their preparation and use
JP2588109B2 (ja) * 1993-03-19 1997-03-05 日本臓器製薬株式会社 鎮痛剤
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
DE19609551C1 (de) 1996-03-12 1997-07-17 Fraunhofer Ges Forschung Biologisch degradierbare und/oder biologisch resorbierbare (Endlos)Fasern, Verfahren zu deren Herstellung und deren Verwendung als Verstärkungsfasern
US6726932B2 (en) * 2000-02-18 2004-04-27 Nippon Zoki Pharmaceutical Co., Ltd. Fatty acid-containing composition
US20040047892A1 (en) * 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
DE102007061873B4 (de) * 2007-01-15 2025-06-26 Bayer Intellectual Property Gmbh Kieselsol-Material zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien, dessen Herstellung und Verwendung
EP3305305B1 (en) * 2007-10-15 2021-06-09 HS Pharmaceuticals, LLC Silicate containing compositions and methods of treatment
DE102008033327A1 (de) * 2008-07-16 2010-01-21 Bayer Innovation Gmbh Kieselsol-Material mit mindestens einem therapeutisch aktiven Wirkstoff zur Herstellung von biologisch degradierbaren und/oder resorbierbaren Kieselgel-Materialien für die Humanmedizin und/oder Medizintechnik
DE102010008981A1 (de) * 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Siliciumhaltiges, biologisch degradierbares Material zur pro-angiogenetischen Therapie

Similar Documents

Publication Publication Date Title
JP2014510590A5 (enExample)
JP2012529484A5 (ja) 高血圧症の防止及び治療のための組成物並びに方法
MX353466B (es) Corticosteroides para el tratamiento de dolor de articulaciones.
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2019005289A (es) Composiciones de corticosteroides administradas oralmente.
MX2014004458A (es) Hebra de acido hialuronico reticulado y metodos de uso de las mismas.
HRP20160427T1 (hr) Fitokanabinoidi u liječenju raka
JP2013517263A5 (enExample)
HK1206270A1 (en) Controlled release formulations for the delivery of hif-1 inhibitors
BR112014029206A2 (pt) pós hemostáticos de celulose regenerada oxidada e métodos para fabricação dos mesmos
WO2011069010A3 (en) Amantadine compositions and methods of use
NZ588913A (en) Liver cancer drug
WO2011148116A3 (fr) Acide hyaluronique modifie, procede de fabrication et utilisations
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
NZ631429A (en) Porous carbon particles for use in the treatment or prevention of liver disease
Zhang et al. Enhancing chronic wound healing through engineering Mg2+-coordinated Asiatic acid/bacterial cellulose hybrid hydrogels
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2015019304A3 (fr) Compositions à libération continue à base d'acide hyaluronique, et leurs applications thérapeutiques
MX343243B (es) Control de aldehidos en productos de cuidado personal.
WO2012051614A3 (en) Delivery of hydrophobic bioactive agents
WO2011044523A3 (en) Compositions and methods for treating obesity
AR077858A1 (es) Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso